Words by GOLD Newsdesk
A new survey from the Association of the British Pharmaceutical Industry (ABPI) has revealed that a surge in apprenticeships, placements and global research collaborations is strengthening the UK’s pharmaceutical workforce.
The ABPI’s biennial ‘Industry and Academic Links’ Survey, released at the opportune time of National Apprenticeship Week, reveals long-term trends in collaborations between pharmaceutical companies and universities. The latest data demonstrates the industry’s efforts to fill skills gaps, advance research and maintain a competitive edge in global life sciences innovation.
Key findings include the industry’s support of apprenticeships across all levels, with 47% at Level 6 (equivalent to a bachelor’s degree) and 17% at Level 7 (equivalent to a master’s) –showcasing a positive commitment to investing in advanced qualifications and specialist skills.
Pharmaceutical companies have also been found to have funded postdoctoral researchers in 27 countries, with nearly half of these researchers based in the UK. In 2024, 699 undergraduate placements were reported, 88% of which lasted one year and span 70 academic institutions across the UK.
“Collaborations between industry and academia are one of the main ways to build up our industry’s future workforce,” commented Andrew Croydon, Director of Education and Examination Policy, ABPI, in a press release. “Both sides are investing in the future of innovation and skills in the UK and these partnerships create unique opportunities for knowledge sharing, benefiting students, universities, businesses and ultimately patients.”
Industry-academic partnerships now also span beyond traditional R&D, with undergraduate placements available across 15 business areas and apprenticeships covering 17 sectors, including IT, manufacturing and marketing. R&D does still, however, remain the most popular field for apprenticeships, accounting for over 40% of all roles.
As the demand for specialised skills increases, partnerships between industry and academia will be essential for maintaining global competitiveness in the sector while creating opportunities for the next generation of scientists and innovators to enter pharma.
